Key Takeaways
- • Sofinnova Partners closed Sofinnova Capital XI at €650 million ($750 million), greatly exceeding its initial fundraising target, according to a Business Wire announcement dated November 16, 2025.
- • Sofinnova's total capital raised across its platform reached €1.5 billion over the past year, per the firm's announcement.
- • Capital XI will back early-stage biopharmaceutical and medtech companies in Europe and North America, participating in both initial and follow-on rounds.
- • The fund drew sovereign wealth funds, pharmaceutical companies, insurers, foundations, and family offices from Europe, North America, Asia, and the Middle East, with a majority of returning LPs.
- • Sofinnova manages over €4 billion in assets and has backed more than 500 companies since its founding in 1972.
Summary
Sofinnova Partners, a life sciences venture capital firm headquartered in Paris with offices in London and Milan, has closed its latest flagship fund, Sofinnova Capital XI, at €650 million ($750 million), according to a Business Wire announcement. The close greatly exceeded the firm's initial target. The firm described the fund as a continuation of its multi-strategy platform model and said Capital XI will back a new generation of biopharmaceutical and medical technology companies addressing unmet clinical needs.
The fund is led by a team of partners including Maina Bhaman, Anta Gkelou, Karl Naegler, Antoine Papiernik, Henrijette Richter, and Graziano Seghezzi. Papiernik, Managing Partner and Chairman of Sofinnova Partners, said the raise "gives us the firepower to double down on early-stage opportunities" and described achieving the milestone in a volatile fundraising environment as a reflection of the strength of the firm's model.
Investor support came from a broad base of institutional backers, including sovereign wealth funds, leading pharmaceutical companies and other corporates, insurance companies, foundations, and family offices. Commitments came from Europe, North America, Asia, and the Middle East. The release said most commitments came from returning LPs, alongside a significant number of new top-tier investors. Total capital raised across Sofinnova's platform reached €1.5 billion over the past year, per the announcement.
Capital XI is already deploying, with investments made in a few portfolio companies. The fund will focus on early-stage biotech and medtech ventures across Europe and North America. Sofinnova, founded in 1972, says it has backed more than 500 companies and manages over €4 billion in assets.
The fund is led by a team of partners including Maina Bhaman, Anta Gkelou, Karl Naegler, Antoine Papiernik, Henrijette Richter, and Graziano Seghezzi. Papiernik, Managing Partner and Chairman of Sofinnova Partners, said the raise "gives us the firepower to double down on early-stage opportunities" and described achieving the milestone in a volatile fundraising environment as a reflection of the strength of the firm's model.
Investor support came from a broad base of institutional backers, including sovereign wealth funds, leading pharmaceutical companies and other corporates, insurance companies, foundations, and family offices. Commitments came from Europe, North America, Asia, and the Middle East. The release said most commitments came from returning LPs, alongside a significant number of new top-tier investors. Total capital raised across Sofinnova's platform reached €1.5 billion over the past year, per the announcement.
Capital XI is already deploying, with investments made in a few portfolio companies. The fund will focus on early-stage biotech and medtech ventures across Europe and North America. Sofinnova, founded in 1972, says it has backed more than 500 companies and manages over €4 billion in assets.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.